

13

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:

Applicant: BRYANT, Joseph L., et al.

Application No.: 10/645,451

Date Filed: August 21, 2003

Title: HIV AND CD4 TRANSGENIC
ANIMALS AND USES
THEREOF

Docket No.: 4115-150 CIP
DIV

Examiner: Not Assigned

Art Unit: Unknown

Customer No.:

23448

FIRST CLASS MAIL CERTIFICATE

I hereby certify that I am mailing the attached documents to the Commissioner for Patents on the date specified, in an envelope addressed to the Mail Stop DD, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, and First Class Mailed under the provisions of 37 CFR 1.8.

Katrina Holland

Katrina Holland

November 19, 2003

Date of Mailing

INFORMATION DISCLOSURE STATEMENT

Mail Stop DD
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449.


Applicants submitted an Information Disclosure Statement on July 2, 2001 in the parent application U.S. Patent Application No. 09/658,256 filed on October 10, 2000. Copies of all references recited on the enclosed PTO Form 1449 have been previously submitted to the United States Patent and Trademark Office.

Applicants request that copies of the previously submitted references be transferred to the file folder of the present application.

Further, applicants have cited four new references that were cited in the parent application U.S. patent application No. 09/658,256 by Examiner Shukla in the February 28, 2002 Office Action, and copies of those references are enclosed (namely, references AC, AI, AJ and AK).

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- ☐ c. Attached is our check no. _____ in the amount of \$_____ in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check no. _____ in the amount of \$180.00 in payment of the petition fee under 37 C.F.R. §1.17(i)(1). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "Marianne Fuierer", is written over a horizontal line.

Marianne Fuierer

Reg. No. 39,983

Attorney for Applicants

INTELLECTUAL PROPERTY/
TECHNOLOGY LAW
Telephone: (919) 419-9350
Fax: (919) 419-9354
Attorney Ref: 4115-150 CIP DIV

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office <div style="border: 1px solid black; border-radius: 50%; padding: 5px; display: inline-block;"> RECEIVED NOV 21 2003 PATENT & TRADEMARK OFFICE </div>		ATTORNEY DOCKET NO. 4115-150 CIP DIV		SERIAL NO. 10/645,451	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				APPLICANT BRYANT, Joseph L., et al.			
				FILING DATE August 21, 2003		GROUP Unknown	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,574,206	11/12/1996	Jolicoeur			08/24/1994
	AB	5,489,742	02/06/1996	Hammer, et al.			06/27/1991
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AC	WO 00/39316	07/06/2000	PCT			
	AD	WO 91/04327	04/04/1991	PCT			
	AE	WO 92/20790	05/14/1992	PCT			
	AF	WO 94/00568	01/06/1994	PCT			
	AG	WO 97/49373	12/31/1997	PCT			
	AH	0 528 360A2	08/13/1992	Europe			
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	AI	Wood, Philip A., "Phenotype Assessment: Are You Missing Something?," Comparative Medicine, Vol. 50, No. 1, pp. 12-15, February 2000					
	AJ	Coffin, John M., et al., "Retroviruses," Retroviral Sequences, pp. 717-718, 1997					
	AK	Lorès, Patrick, et al., "Expression of Human CD4 in Transgenic Mice Does Not Confer Sensitivity to Human Immunodeficiency Virus Infection," Aids Research and Human Retroviruses, Vol. 8, No. 12, pp. 2063-2071, 1992					
	AL	Berthold, E., et al., "cis-Acting Elements in Human Immunodeficiency Virus Type I RNAs Direct Viral Transcript to Distinct Intranuclear Locations," Journal of Virology, patent, pp. 4667-4682, July 1996					
	AM	Clements JE, et al., Clinical Microbiol. Rev. 9, pp. 100-117, 1998					
	AN	Connor, R., et al., "Characterization of the Functional Properties of env Genes from Long-Term Survivors of Human Immunodeficiency Virus Type 1 Infection," Journal of Virology, patent, pp. 5306-5311, August 1996					
	AO	De, S., et al., "Human Chorionic Gonadotropin Hormone Prevents Wasting Syndrome and Death in HIV-1 Transgenic Mice," The Journal of Clinical Investigation, Vol. 99, No. 7, patent, pp. 1484-1491, April, 1997					
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

* All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office NOV 21 2003		ATTORNEY DOCKET NO. 4115-150 CIP DIV		SERIAL NO. 10/645,451	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				APPLICANT BRYANT, Joseph L., et al.			
				FILING DATE August 21, 2003		GROUP Unknown	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	AP	Dickie, P., et al., Virology 185, pp. 109-119, 1991					
	AQ	Dickie, Peter, "HIV Type 1 Nef Perturbs Eye Lens Development in Transgenic Mice," Aides Research and Human Retroviruses, Vol. 12, No. 3, 1996					
	AR	Dickie, Peter, "Models of HIB Type 1 Proviral Gene Expression in Wild-Type HIV and MLV/HIV Transgenic Mice," Aids Research and Human Retroviruses, Vol. 12, No. 12, 1996					
	AS	Finco, O., et al., "Induction of CD4 + T Cell Depletion in Mice Doubly Transgenic for HIV gp120 and Human CD4," Eur. J. Immunol. Vol. 27, no. 6, June 1997, pp 1319-1324, XP002114694					
	AT	Hopp, T., "Human Chorionic Gonadotropin Hoodwinks Gallo," Nature Biotechnology 15, p. 834, October 1997					
	AU	International Search Report for PCT/US98/07821 dated 22 September 1999					
	AV	Klotman, P., et al., "Transgenic Models of Human Immunodeficiency Virus Type-1" Curr. Top. Microbiol. Ummunol., Vol. 206, pp. 197-122, XP002114694, 1996					
	AW	Leonard, J., et al., "Development of Disease and Virus Recovery in Transgenic Mice Containing HIV Proviral DNA," Research Articles, patent, pp. 1665-1670, December 23, 1988					
	AX	Naldini et al., "Efficient Transfer, integration, and Sustained Long-term Expression of the Transgene in Adult Rat Brains Injected With a Lentiviral Vector," Proc. Natl. Acad. Sci. USA, Vol. 93, No. 21, pp. 11383-11388, XP002114690, October 15, 1996					
	AY	Ray, P., et al., "bFGF and its Low Affinity Receptors in the Pathogenesis of HIV-Associated Nephropathy in Transgenic Mice," Klaney International, Vol. 40, patent, pp. 759-772, 1994					
	AZ	Santoro et al., "Growth Failure and Aids-like Cachexia Syndrome in HIV-1 Transgenic Mice," Virology, 201, p. 197, 1993					
	BA	Tinkle BT, et al., J. Clin Invest. 100, pp. 32-39, 1997					
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

* All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

23448

Page 3 of 3

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. 4115-150 CIP DIV		SERIAL NO. 10/645,451	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				APPLICANT BRYANT, Joseph L., et al.			
				FILING DATE August 21, 2003		GROUP Unknown	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	BB	Whimer, et al., "HIV-1 Expression During Early Mammalian Development," AIDS, Vol. 6, No. 10, 1992					
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

* All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).